PATIENT SURVIVAL WITH ypT0N+ FOLLOWING NEOADJUVANT THERAPY IN GASTRIC AND RECTAL CANCERS

Abstract

Background Survival outcomes of gastric and rectal cancer patients who developed ypT0N+ remain poorly characterized. Methods A survival analysis of the NCDB was conducted on patients with gastric or rectal adenocarcinoma who underwent neoadjuvant therapy and surgery. Results Among gastric cancer patients, achieving ypT0N+ was associated with lower 5-year and 3-year overall survival (OS) than ypT0N0 and ypT1-2N0. There were no differences in 1-year OS between ypT0N+ and ypT0N0 or ypT1-2N0. There were also no differences in 5-year, 3-year, or 1-year OS between ypT0N+ and ypT3-4N0 or ypT1-2N+. Developing ypT0N+ was associated with a higher 5-year OS than ypT3-4N+. There were no differences in 3-year or 1-year OS between ypT0N+ and ypT3-4N+. . Among rectal cancer patients who received total neoadjuvant therapy, developing ypT0N+ was associated with a lower 5-year OS than ypT0N0 and ypT1-2N0. However, ypT0N+ disease was associated with a higher 5-year OS than ypT3-4N+. There were no differences in 5-year OS between ypT0N+ and ypT3-4N0 or ypT1-2N+. Similar findings were noticed among rectal cancer patients who received neoadjuvant chemoradiation and adjuvant chemotherapy. Conclusion Developing ypT0N+ was associated with a lower 5-year OS than ypT0N0 and ypT1-2N0 and a higher 5-year OS than ypT3-4N+ in both gastric and rectal cancers.